Beta blocker effects on plasma homocysteine levels in patients with hypertension

Area of Science:

• Cardiology
• Clinical Pharmacology
• Metabolic Syndrome

Background:

• Hyperhomocysteinemia is increasingly recognized as a potential factor in hypertension development.
• The impact of antihypertensive medications on homocysteine levels requires further investigation.
• Beta-blockers are widely used for hypertension, but their effect on homocysteine is not well-established.

Purpose of the Study:

• To evaluate the effect of metoprolol succinate, a beta-blocker, on plasma homocysteine levels in patients with newly diagnosed hypertension.
• To determine if blood pressure control influences homocysteine reduction.
• To explore potential differences in homocysteine reduction between sexes.

Main Methods:

• A study involving 120 newly diagnosed hypertensive patients initiated on metoprolol succinate 100 mg/day.
• Dosage adjustment of metoprolol succinate based on blood pressure readings.
• Measurement of plasma homocysteine levels before treatment and after four months of therapy.

Main Results:

• A statistically significant decrease in homocysteine levels was observed after four months of metoprolol succinate treatment (P = 0.001).
• No correlation was found between homocysteine levels and the degree of blood pressure control.
• Homocysteine levels significantly decreased in women (P = 0.001) but not in men (P = 0.185).

Conclusions:

• Metoprolol succinate treatment effectively reduces plasma homocysteine levels in hypertensive individuals.
• The homocysteine-lowering effect of metoprolol succinate is more pronounced in women.
• These findings suggest metoprolol succinate may have beneficial metabolic effects beyond blood pressure reduction in hypertension, particularly in women.